 |
United Therapeutics' oral treprostinil fails Phase III PAH trial
Thursday 20 November 2008
Katie McQue - Reporter
United Therapeutics' oral treprostinil has failed its pivotal Phase III trial, FREEDOM-C, testing it as an adjunctive treatment in pulmonary arterial hypertension (PAH).
The announcement, which came in conjunction with an unveiling of a $150million licensing deal to commercialise Lilly's PAH drug, tadalafil, nevertheless drove shares down by 36%, closing at $58.62, a 52-week low, on November 17th...
Login to view the full article
- Not a subscriber? Request a FREE trial
- Subscribe to Scrip
- Email to a friend
Comments
No Comments Yet
About Scrip
Scrip World Pharmaceutical News provides you with high quality news coverage of pharma and biotech and also gives you strategic data and analysis.
Benefits include:
›› Daily email headlines
›› Searchable news
archive
›› Weekly copies of Scrip
›› Bespoke Scrip supplements
›› Plus the Scrip Yearbook
and Scrip League Tables
Scrip Awards 2008
The best and brightest of the pharmaceutical and biotech industries were celebrated at a glittering ceremony in London at the 2008 Scrip Awards.
Read the full story
Scrip Directory
Scrip Directory 2008
Search over 20,000 international contacts and access potential business opportunities
© Informa plc. All rights reserved. This site is owned and operated by Informa plc ("Informa") whose registered office is
Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
